Eli Lilly (LLY) Short-Term Debt issuances (2016 - 2025)
Historic Short-Term Debt issuances for Eli Lilly (LLY) over the last 16 years, with Q3 2025 value amounting to -$4.1 billion.
- Eli Lilly's Short-Term Debt issuances fell 3244.32% to -$4.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 billion, marking a year-over-year decrease of 33219.89%. This contributed to the annual value of -$1.9 billion for FY2024, which is 13947.22% down from last year.
- Latest data reveals that Eli Lilly reported Short-Term Debt issuances of -$4.1 billion as of Q3 2025, which was down 3244.32% from $1.6 billion recorded in Q2 2025.
- Eli Lilly's Short-Term Debt issuances' 5-year high stood at $4.6 billion during Q4 2023, with a 5-year trough of -$5.2 billion in Q1 2024.
- Moreover, its 5-year median value for Short-Term Debt issuances was -$100.1 million (2021), whereas its average is -$12.5 million.
- Its Short-Term Debt issuances has fluctuated over the past 5 years, first tumbled by 963200.0% in 2022, then skyrocketed by 198836.83% in 2023.
- Quarter analysis of 5 years shows Eli Lilly's Short-Term Debt issuances stood at -$2.5 million in 2021, then plummeted by 9632.0% to -$243.3 million in 2022, then soared by 1988.37% to $4.6 billion in 2023, then plummeted by 33.78% to $3.0 billion in 2024, then tumbled by 234.49% to -$4.1 billion in 2025.
- Its Short-Term Debt issuances was -$4.1 billion in Q3 2025, compared to $1.6 billion in Q2 2025 and -$1.8 billion in Q1 2025.